Bicara Therapeutics (BCAX) Net Income towards Common Stockholders (2023 - 2026)

Bicara Therapeutics' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 52.56% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$157.3 million (down 70.38% YoY), while the FY2025 annual figure was -$138.0 million, down 102.88% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$56.2 million, down from -$37.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$12.4 million in Q4 2023, with the low at -$56.2 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$22.8 million (2023), against an average of -$27.0 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders grew 23.48% in 2024, then plunged 194.58% in 2025.
• Bicara Therapeutics' Net Income towards Common Stockholders stood at -$12.4 million in 2023, then sank by 68.46% to -$21.0 million in 2024, then plunged by 78.39% to -$37.4 million in 2025, then slumped by 50.35% to -$56.2 million in 2026.
• Business Quant data shows BCAX's Net Income towards Common Stockholders at -$56.2 million in Q1 2026, -$37.4 million in Q4 2025, and -$36.3 million in Q3 2025.